EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis

To quantify the long-term comparative efficacy of nivolumab plus ipilimumab (NIVO + IPI) relative to other immunotherapy (IO)-based regimens in patients with first-line metastatic non-small cell lung cancer (mNSCLC) and tumor programmed death ligand 1 (PD-L1) < 1%, a population with large unmet need.